Simcere Pharmaceutical Group Limited (Simcere Pharma) on 22 May 2026 announced the publication of its latest Circular, Notice of Annual General Meeting and Proxy Form in both English and Chinese. These documents are now accessible on the company’s website (www.simcere.com) and the HKEXnews platform (www.hkexnews.hk). Printed versions have been dispatched only to newly registered shareholders who have not previously indicated their communication preferences.

To comply with the paperless listing regime—effective on the Hong Kong Stock Exchange since 31 December 2023—the board confirmed that all future corporate communications, including directors’ reports, annual and interim reports, meeting notices, circulars and proxy forms, will be provided electronically.

Shareholders are requested to supply a functional email address by completing and returning the enclosed Reply Form to Computershare Hong Kong Investor Services Limited by 20 June 2026. If no response is received by that date, shareholders will be deemed to have consented to receive all future communications via the company’s website.

For those opting into the website version, the email address will be used for: 1) real-time notifications when new documents are posted on Simcere Pharma’s website, and 2) delivery of all future “Actionable Corporate Communications” (materials requiring shareholder instructions).

If no valid email address is provided, Simcere Pharma will mail a hard-copy notification of each web posting and continue to send Actionable Corporate Communications in printed form until an email is supplied.

Shareholders preferring printed communications may indicate this on the Reply Form or email simcere.ecom@computershare.com.hk. Such instructions remain valid for one year from receipt unless revoked.

Queries can be directed to the shareholder hotline on +86 (25) 8556 6666, Monday to Friday, 9:00 a.m. to 5:00 p.m.

The board is chaired by Executive Director Mr Ren Jinsheng, who signed the notification on behalf of Simcere Pharma.